A Study of Olanzapine in Participants With Bipolar Disorder.

Recruiting now

Conditions studied: Bipolar Disorder

In brief

This study aimed to identify treatment patterns in patients with bipolar disorder receiving olanzapine according to demographic and clinical characteristics and to evaluate the effectiveness of education on weight gain, a side effect of olanzapine, in preventing weight gain.

Key facts

Study ID

NCT07263191

Run by

Boryung Pharmaceutical Co., Ltd

People needed

3000

Starts

2025-10-30

Expected to finish

2027-09-01

Last updated by the study team

2025-12-04

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who have signed the informed consent after receiving information about the purpose and method of this study.
• Patients diagnosed with bipolar disorder and scheduled to receive olanzapine.
• Patients who understand the contents of the survey and can answer the questions directly.

You may not qualify if…

• Female patients who are pregnant, have childbearing potential, or are breastfeeding.
• Has received an investigational product within 12 weeks from the study enrollment or has plans to participate in another clinical trial during the participation of this study.
• Other subjects who are considered inappropriate to participate in this study by the judgment of the investigator.

Where it is running

• CHA Bundang Medical Center — Seongnam, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.